Bird & Bird advises Bpifrance on US$87M investment
Bird & Bird has advised Bpifrance on its participation in Arthex Biotech’s $87 million series B financing round. Arthex, a spin-off from the University of Valencia, develops targeted RNA therapies for rare genetic neuromuscular disorders.
The series B extension was led by Bpifrance under its Large Venture and InnoBio strategies, with participation from existing investors including AdBio Partners, CDTI Innovación, Columbus Venture Partners, European Innovation Council, Hadean Ventures, Invivo Partners, and Sound Bioventures.
Funds will support the global clinical development of Arthex’s lead program, ATX-01, targeting Myotonic Dystrophy Type 1 (DM1). This includes the ongoing Phase I/IIa ArthemiRTM trial and preparation for an open-label extension for a registrational study. The financing will also advance the company’s pipeline of RNA-based medicines for muscular, central nervous system, and cardiac disorders. ATX-01 has received Orphan Drug Designation in both the US and EU.
On this transaction, Bird & Bird counted on a cross-border team comprising partner Carole Bodin and associate Jasmine Javault, from the Paris office, and partner Lourdes Ayala, counsel Antonio Ballesteros and associate Adrian Bert, from the Madrid office.
On the picture, from left to right, Carole Bodin and Lourdes Ayala.
